A newly approved multiple sclerosis medication promises to restore walking ability for thousands of people across England. Fampridine, a drug that enhances nerve signal transmission in the spinal cord, has entered the NHS formulary after years of restricted access.
The medication works by blocking potassium channels in nerve cells, allowing electrical signals to travel more efficiently across damaged myelin. This mechanism helps compensate for the nerve damage that characterizes MS, making walking less effortful and safer.
NHS England estimates approximately 5,000 people with MS will qualify for fampridine. The drug targets adults whose mobility has been significantly compromised by their condition. Clinical trials demonstrate that users experience measurable improvements in walking speed and endurance, with some patients reporting they can walk further without assistance or remain standing longer without fatigue.
People with progressive forms of MS, including secondary progressive and primary progressive types, stand to benefit most. The medication works specifically for those with walking difficulties stemming from spinal cord involvement. Patients don't need to show active inflammation to qualify.
Fampridine represents a shift in MS treatment focus. While disease-modifying therapies target immune activity, fampridine addresses the functional consequences of existing nerve damage. This allows it to help people across different disease stages and disease-modifying therapy regimens.
The approval follows a lengthy campaign by MS organizations and patients advocating for NHS access. Previously, only those with specific healthcare funding arrangements could afford the drug privately, creating stark disparities in who could access its benefits.
Dr. Heather Jones, medical director at the MS Society, emphasized that this approval validates what patients have long understood. Walking difficulties profoundly impact quality of life, employment, and independence. Fampridine offers genuine restoration of function rather than mere symptom management.
The drug requires a prescription from an MS specialist and regular monitoring. Common side effects include dizz